RNL (rhenium-186-chelated nanoliposome) - Plus Therap
ReSPECT-LM: Intraventricular Administration of Rhenium-186 NanoLiposome for Leptomeningeal Metastases (clinicaltrials.gov) - Sep 5, 2021 - P1; N=18; Not yet recruiting; Sponsor: Plus Therapeutics 
Clinical • New P1 trial • Oncology
http://clinicaltrials.gov/ct2/show/NCT05034497
 
Sep 5, 2021
 
Prev Next